期刊
MOVEMENT DISORDERS
卷 26, 期 8, 页码 1552-1555出版社
WILEY
DOI: 10.1002/mds.23687
关键词
Parkinson's disease; levodopa; dyskinesia; levetiracetam
资金
- UCB Pharma
Background: This randomized double blind, placebo-controlled crossover study investigated the antidyskinetic effects of levetiracetam in Parkinson's disease. Methods: Sixteen participants with levodopa-induced dyskinesia were enrolled. Hourly videotaped dyskinesia assessments scored by the Goetz method and hourly Unified Parkinson's Disease Rating Scale motor sub-scale scoring were conducted on 1 day at the end of each treatment period. Results: Dyskinesia was slightly less on placebo (P = .26). Patient diary records also showed less dyskinesia on placebo (P = .10). Parkinsonism was a little worse on levetiracetam, at borderline statistical significance (P = .05). Conclusions: Levetiracetam was well tolerated at doses up to 2000 mg per day, but we did not detect any antidyskinetic properties. (C) 2011 Movement Disorder Society
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据